DaVita Clinical Research to Present Results on Safety of Biosimilars, Treating Depression, Burden of Diabetic Foot Ulcers

Posted by: DaVita Clinical Research

LAS VEGAS (April 22, 2014) DaVita Clinical Research (DCR), a specialty contract research organization with services spanning the full spectrum of drug and device development, today announced that company representatives will present four abstracts at National Kidney Foundation’s (NKF) 2014 Spring Clinical Meeting, which takes place April 22-26, 2014 in Las Vegas.

The NKF Spring Clinical Meeting is a platform for the nation’s leading kidney care providers to learn about new developments related to all aspects of nephrology and is expected to attract nearly 3,000 health care professionals in 2014.

Representatives from DaVita, the kidney care division of DaVita Healthcare Partners Inc., and DCR will present results from both DaVita’s innovative clinical quality initiatives and clinical research originating from DCR and its research partners.

“Our goal at DaVita is to move up the clinical pyramid and improve mortality, morbidity and patient quality of life. Innovating through clinical quality initiatives is one important way we do that,” said Mahesh Krishnan, M.D., M.P.H., M.B.A., F.A.S.N., vice president of clinical innovation and public policy at DaVita. “Translational research and meaningful quality initiatives, as are included among these abstracts, are essential for improving health care. These findings further solidify DaVita’s commitment to investing in improved patient outcomes.”

DaVita will share the results from the following clinical quality initiatives during the poster session on April 23, from 6:00 to 7:30 p.m.:

  • “Treating depression in the dialysis setting: validating Symptom Targeted Intervention,” presented by Shaun Boyd, L.S.W., poster 155
  • “Root Causes of Lack of Adherence to Mineral Bone Disease (MBD) Medication in ESRD Patients,” presented by Maureen McKinley, L.S.W., poster 408

In addition, the findings from the following health outcomes research studies will be presented during the poster session scheduled for April 23, from 6:00 p.m. to 7:30 p.m.:

  • “Economic Impact of Ferric Citrate (FC) versus Standard of Care for Hemodialysis Patients,” presented by Steven M. Brunelli, M.D., M.S.C.E., poster 156
  • “Disease Burden of Diabetic Foot Ulcers in End-Stage Renal Disease,” presented by Scott Sibbel, Ph.D., M.P.H., poster 221

DCR seeks to advance the future of medicine, the practice of medicine and to innovate through personalized medicine. DCR and DaVita share a dedication to improving the health and quality of life for kidney care patients.

DaVita, DaVita Clinical Research and DCR are trademarks or registered trademarks of DaVita Healthcare Partners Inc. All other trademarks are the property of their respective owners.


About DaVita HealthCare Partners Inc.

DaVita HealthCare Partners Inc., a Fortune 500® company, is the parent company of DaVita Kidney Care and HealthCare Partners. DaVita Kidney Care is a leading provider of kidney care in the United States and abroad, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. As of Dec. 31, 2013, DaVita Kidney Care operated or provided administrative services at 2,074 outpatient dialysis centers in the United States serving approximately 168,000 patients, and at 73 centers in 10 countries outside of the United States. HealthCare Partners® manages and operates medical groups and affiliated physician networks in California, Nevada, Florida, Arizona and New Mexico in its pursuit to deliver excellent-quality health care in a dignified and compassionate manner. As of Dec. 31, 2013, HealthCare Partners provided integrated care management for approximately 765,000 managed care patients. For more information, please visit DaVitaHealthCarePartners.com.


About DaVita Clinical Research

DaVita Clinical Research (DCR), a wholly owned subsidiary of DaVita HealthCare Partners Inc., uses its extensive, applied database and real-world healthcare experience to assist pharmaceutical and medical device companies in the design, recruitment, and completion of clinical trials including retrospective and prospective pragmatic trials. DCR’s scientific and clinical expertise spans the lifecycle of product development with more than 150 client companies. DCR’s BiorepositoryEarly Clinical Research unit (Phase I-IIa) and Late Phase Clinical Research (Phase IIb through post-marketing) network of physicians and investigative sites, data research, Health Economics & Outcomes ResearchCentral Laboratory, and Medical Communications are focused on providing world-class research in both complex/specialty populations and therapeutic areas, and especially in CKD and ESRD populations. To learn more about DCR, visit www.davitaclinicalresearch.com.


Contact Information

Bianca Violante

Office: (303) 876-6614
Mobile: (443) 417-6044